OpenBilldrug price receipt

NADAC week of 2026-10-14

AVALIDE 150-12.5 MG TABLET

FDA nonproprietary name: irbesartan and hydrochlorothiazide

For 30 tablets

Pharmacies pay

$267.33 filed

30 × $8.91093 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2025-10-22 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$276.44 filed

30 × $9.21474 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

1.0× estimated

Medicare paid about what pharmacies pay.

Part D averages every strength and form sold under “Avalide” / “Irbesartan/Hydrochlorothiazide” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2025-10-22 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$312.43 estimated

$267.33 + $40.10 (15%) + $5.00 fee per fill = $312.43

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2025-10-22 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

AVALIDE 150-12.5 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as irbesartan and hydrochlorothiazide, under the trade name “Avalide”.

FDA gives its dosage form as tablet, film coated and its route as oral.

The labeler, the company named on the label, is Sanofi-Aventis U.S. LLC.

FDA lists it under 2 Established Pharmacologic Classes: Angiotensin 2 Receptor Blocker and Thiazide Diuretic.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 00024-5855-30.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $267.33 for 30 tablets (30 × $8.91093 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2025-10-22. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 4, carried forward from the previous file.

This NDC’s NADAC was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: it took effect on 2025-10-22. The file is new; the price is not.

NADAC also lists, on the row of one brand NDC, what pharmacies pay for the generic equivalent, a different product: $0.14881 per EA filed.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

The NDC

Other strengths, forms and brands

2 other products in the NADAC file share the FDA nonproprietary name irbesartan and hydrochlorothiazide with AVALIDE 150-12.5 MG TABLET.

ProductPharmacies pay per unitMedicare per unit
AVALIDE 150-12.5 MG TABLET this page
brand · tablet, film coated
$8.91093 per EA filed
eff. 2025-10-22
$9.21474 per EA filed
Part D 2024 average
IRBESARTAN-HYDROCHLOROTHIAZIDE 150-12.5 MG TB
generic · tablet, film coated / tablet
$0.14881 per EA filed
eff. 2026-09-23
$0.31241 per EA filed
Part D 2024 average
IRBESARTAN-HYDROCHLOROTHIAZIDE 300-12.5 MG TB
generic · tablet, film coated / tablet
$0.1881 per EA filed
eff. 2026-09-23
$0.31241 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2025-10-22, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

Its NADAC price is $8.91093 per EA filed.

Of the 107 other products in FDA’s Angiotensin 2 Receptor Blocker class priced per EA, 25 have a higher middle NADAC price and 82 a lower one. The one in the middle is CANDESARTAN-HYDROCHLOROTHIAZIDE 32-25 MG TAB, at $1.07781 per EA filed (eff. 2026-09-23).

Of the 68 other products in FDA’s Thiazide Diuretic class priced per EA, 7 have a higher middle NADAC price and 61 a lower one. The one in the middle is TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB, at $0.3567 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2025-10-22, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $276.44 for 30 tablets, at an average of $9.21474 per EA in 2024 (2024-01-01 to 2024-12-31) for “Avalide” and “Irbesartan/Hydrochlorothiazide”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 1,141 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for AVALIDE 150-12.5 MG TABLET labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Avalide / Irbesartan/Hydrochlorothiazide: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.